Medicare Enrolled
Dr. Padmaja Venuturumilli, MD
Pediatrics · Royal Oak, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Venuturumilli from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Venuturumilli?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Venuturumilli
Dr. Padmaja Venuturumilli is a pediatrics specialist in Royal Oak, MI, with 19 years of NPI registration. Based on federal Medicare data, Dr. Venuturumilli performed 84,788 Medicare services across 3,531 unique beneficiaries.
Between the years covered by Open Payments, Dr. Venuturumilli received a total of $6,619 from 66 pharmaceutical and/or device companies across 305 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pediatrics. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Venuturumilli is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in MI
$6,619 industry payments
Medicare Practice Summary
Medicare Utilization ↗84,788
Medicare services
Top 1% in MI for pediatrics
3,531
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,463 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
24,990 | $0 | $2 |
| Filgrastim injection (Nivestym) for white blood cells An injection of the biosimilar medication filgrastim-aafi (Nivestym) at a dose of 1 microgram. |
23,400 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,150 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 6,000 | $43 | $105 |
| Denosumab injection (Prolia/Xgeva) | 5,760 | $18 | $43 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
1,645 | $4 | $59 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,330 | $1 | $40 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,249 | $8 | $11 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,228 | $7 | $25 |
| Injection, leucovorin calcium, per 50 mg | 1,056 | $3 | $30 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,011 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
810 | $6 | $17 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
730 | $6 | $17 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
657 | $2 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
573 | $95 | $265 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
465 | $71 | $185 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
415 | $12 | $40 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
352 | $11 | $36 |
| Liver function blood test panel | 280 | $8 | $17 |
| Basic metabolic blood panel A blood test that measures a group of basic chemicals, including total calcium levels. |
279 | $8 | $17 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
274 | $10 | $22 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
264 | $101 | $276 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 255 | $3 | $22 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
230 | $64 | $148 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
226 | $7 | $14 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
208 | $1 | $2 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
200 | $6 | $13 |
| Phosphate level test A blood test that measures the amount of phosphate in your body. Phosphate is a mineral that helps keep bones and teeth strong. |
200 | $5 | $10 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
198 | $4 | $10 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
114 | $1 | $4 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
104 | $23 | $61 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
102 | $51 | $134 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
100 | $24 | $95 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
91 | $10 | $40 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
91 | $58 | $153 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
82 | $7 | $20 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
76 | $20 | $59 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
72 | $50 | $136 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
71 | $88 | $270 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
71 | $141 | $397 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
59 | $1 | $3 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
49 | $36 | $116 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
46 | $13 | $41 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
46 | $29 | $79 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
35 | $140 | $365 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
34 | $16 | $47 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
31 | $70 | $205 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
30 | $1 | $3 |
| New patient office visit, complex (60-74 min) | 27 | $174 | $455 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
11 | $20 | $55 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $135 | $339 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.3% high complexity
62.9% medium
6.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,619
Total received (2018-2024)
Avg $946/year across 7 years
Top 4% in MI for pediatrics
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
66
Companies
305
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,931 (74.5%)
Other
Charitable contributions, space rental, and other categories
$1,254 (18.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$434 (6.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,435
2023
$1,293
2022
$1,550
2021
$122
2020
$145
2019
$799
2018
$276
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,254
Eisai Inc.
$135
Merck Sharp & Dohme LLC
$98
Gilead Sciences, Inc.
$88
Genentech USA, Inc.
$88
Janssen Biotech, Inc.
$77
PFIZER INC.
$74
AstraZeneca Pharmaceuticals LP
$66
Rigel Pharmaceuticals, Inc.
$60
TAIHO ONCOLOGY, INC.
$42
Takeda Pharmaceuticals U.S.A., Inc.
$35
Celgene Corporation
$34
ABBVIE INC.
$32
Acrotech Biopharma Inc.
$29
Immunocore Limited
$26
Octapharma USA, Inc.
$25
Genmab U.S., Inc.
$24
BeiGene USA, Inc.
$23
PUMA BIOTECHNOLOGY, INC.
$23
Kite Pharma, Inc.
$22
Tempus AI, Inc
$22
Incyte Corporation
$22
GENZYME CORPORATION
$20
Sumitomo Pharma America, Inc.
$20
Alexion Pharmaceuticals, Inc.
$20
ARRAY BIOPHARMA INC
$18
Agios Pharmaceuticals, Inc.
$16
TerSera Therapeutics LLC
$15
Aveo Pharmaceuticals, Inc.
$15
SERVIER PHARMACEUTICALS LLC
$14
Top 3 companies account for 61.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,554
Amgen Inc.
$458
Genentech USA, Inc.
$415
PFIZER INC.
$307
Janssen Biotech, Inc.
$276
Eisai Inc.
$221
AstraZeneca Pharmaceuticals LP
$212
Merck Sharp & Dohme LLC
$200
Astellas Pharma US Inc
$192
Gilead Sciences, Inc.
$185
GENZYME CORPORATION
$164
Celgene Corporation
$148
E.R. Squibb & Sons, L.L.C.
$145
Focal Therapeutics, Inc.
$129
Seagen Inc.
$121
Lilly USA, LLC
$116
Takeda Pharmaceuticals U.S.A., Inc.
$109
Rigel Pharmaceuticals, Inc.
$92
Genmab U.S., Inc.
$92
Alexion Pharmaceuticals, Inc.
$84
EISAI INC.
$74
Kite Pharma, Inc.
$71
AMAG Pharmaceuticals, Inc.
$68
Merck Sharp & Dohme Corporation
$62
ARRAY BIOPHARMA INC
$62
BeiGene USA, Inc.
$61
Acrotech Biopharma Inc.
$53
Deciphera Pharmaceuticals Inc.
$53
Daiichi Sankyo Inc.
$51
PharmaEssentia USA Corporation
$50
ABBVIE INC.
$50
TerSera Therapeutics LLC
$48
EMD Serono, Inc.
$45
TAIHO ONCOLOGY, INC.
$42
PUMA BIOTECHNOLOGY, INC.
$40
Incyte Corporation
$35
Emmaus Medical, Inc.
$29
Pharmacyclics LLC, an AbbVie Company
$28
Exelixis Inc.
$27
Immunocore Limited
$26
Octapharma USA, Inc.
$25
Tempus AI, Inc
$22
ADC Therapeutics America, Inc.
$21
Sumitomo Pharma America, Inc.
$20
G1 Therapeutics, Inc.
$18
Bayer Healthcare Pharmaceuticals Inc.
$18
Apellis Pharmaceuticals, Inc.
$18
Fortovia Therapeutics, Inc.
$17
Ipsen Biopharmaceuticals, Inc
$17
Pharmacyclics LLC, An AbbVie Company
$17
Stemline Therapeutics Inc.
$16
Agios Pharmaceuticals, Inc.
$16
Spectrum Pharmaceuticals Inc.
$16
SANOFI-AVENTIS U.S. LLC
$15
AbbVie, Inc.
$15
Taiho Oncology, Inc.
$15
Aveo Pharmaceuticals, Inc.
$15
Kyowa Kirin, Inc.
$15
GlaxoSmithKline, LLC.
$14
SERVIER PHARMACEUTICALS LLC
$14
Puma Biotechnology, Inc.
$14
Janssen Pharmaceuticals, Inc
$13
MorphoSys, US Inc.
$13
Bayer HealthCare Pharmaceuticals Inc.
$13
Innate Pharma, Inc
$12
Lexicon Pharmaceuticals, Inc.
$12
Top 3 companies account for 36.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ALTUVIIIO · Alecensa · Avastin · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · BioZorb · Blincyto · CABOMETYX · CALQUENCE · CHANTIX · COSELA · Cabometyx · Columvi · DARZALEX · ELIQUIS · ELITEK · EMPLICITI · ENJAYMO · EPKINLY · Empaveli · Endari · Enhertu · Epkinly · FERAHEME · FOTIVDA · GAUCHER-DISEASE · GAZYVA · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lumoxiti · MEKINIST · MONJUVI · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Perjeta · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · Soltamox · Stivarga · TAGRISSO · TALZENNA · TECENTRIQ · TEPMETKO · TUKYSA · Tavalisse · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VPRIV · VYNDAQEL · Vectibix · Venclexta · XARELTO · XTANDI · Xermelo · Xtandi · Yescarta · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (74%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 4% for pediatrics in MI.
Geographic Context
Pediatricians within 10 mi
1,009
Per 100K population
79.3
County median income
$95,296
Nearest hospital
BEAUMONT HOSPITAL ROYAL OAK
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Venuturumilli is a mixed practice specialist, with above-average Medicare volume (top 1% in MI), with low-engagement industry engagement in the top 4% of MI peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Venuturumilli experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Venuturumilli performed 24,990 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Venuturumilli receive payments from pharmaceutical companies?
Yes. Dr. Venuturumilli received a total of $6,619 from 66 companies across 305 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Venuturumilli's costs compare to other pediatricians in Royal Oak?
Dr. Venuturumilli's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Venuturumilli) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Pediatricians in Royal Oak
Browse pediatricians in Royal Oak ranked by procedure volume and transparency data.
Highest volume
Top Pediatricians in MI
Pediatricians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pediatricians in MI
Which MI pediatricians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology